Overview

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Participants With Atopic Dermatitis

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-10-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability, drug levels, drug effects, and impact on disease severity of BMS-986326 in participants with moderate-to-severe atopic dermatitis (AD).
Phase:
PHASE1
Details
Lead Sponsor:
Bristol-Myers Squibb